Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

NCT00574275 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00574275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00574275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2007
Completion date
November 30, 2010
Enrollment
546 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasm